MATINAS BIOPHARMA HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $34.76 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2014-03-31 was $0.94.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $34.76, a 25.57% decline from fiscal 2024.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $46.70, a 3857.63% increase from fiscal 2023.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $1.18, a 4.07% decline from fiscal 2022.
- MATINAS BIOPHARMA HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $1.23, a 2.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2025-12-31 | $34.76 10-K · filed 2026-03-31 | ||
| 2024-12-31 | $46.70 10-K · filed 2025-04-15 | ||
| 2023-12-31 | $1.18 10-K · filed 2024-03-27 | ||
| 2022-12-31 | $1.23 10-K · filed 2023-03-15 | ||
| 2021-12-31 | $1.20 10-K/A · filed 2022-03-11 | ||
| 2014-06-30 | $0.94 10-Q · filed 2014-08-08 | ||
| 2014-03-31 | $0.94 10-Q · filed 2014-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |